| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Letters to the Editor |
Neurochirurgische Klinik der Universität Erlangen-Nürnberg Erlangen, Germany 91054
In the January issue of The Journal of Clinical Endocrinology and Metabolism, a paper was published by Shimon et al. (1) on the direct effects of GHRP on human pituitary GH secretion, in which it was stated "...whereas all in vitro studies have employed rodent, bovine, or ovine pituitary cells" (last paragraph of Introduction) and "we have used a unique model of human pituitary cells in primary culture to show, for the first time, direct effects of GHRP on human pituitary GH secretion" (Discussion, 3rd paragraph). Whilst we agree that this is the first study to examine the direct effects of GHRP on normal human fetal pituitary cells, there have certainly been a number of previously published studies on human pituitary somatotroph responsiveness to GHRP in vitro, including two in Endocrine Society journals (2, 3). Credit should also be given to Bressin-Bepoldin et al. (4) and Lei et al. (5), who both reported on the intracellular mechanism of action of GHRP on human somatotrophs in culture.
We appreciate how difficult it is for journals and authors to be aware of all previous publications in a particular area but feel, in this case, that the statements by Shimon et al. unfairly dilute the significant contribution made by other groups in the very important area of synthetic growth hormone secretagogues.
Footnotes
Address correspondence to: Eric Adams, Ph.D., Neuroendokrinologisches Labor, Neurochirurgische Klinik der Universität Erlangen-Nürnberg, Schwabachanlage 6, Erlangen, Germany 91054.
Received March 18, 1998.
References
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |